We studied genes involved in pancreatic β cell function and survival, identifying associations between SNPs in WFS1 and diabetes risk in UK populations that we replicated in an Ashkenazi population and in additional UK studies. In a pooled analysis comprising 9,533 cases and 11,389 controls, SNPs in WFS1 were strongly associated with diabetes risk. Rare mutations in WFS1 cause Wolfram syndrome; using a gene-centric approach, we show that variation in WFS1 also predisposes to common type 2 diabetes.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gloyn, A.L. et al. Diabetes 52, 568–572 (2003).
Nielsen, E.M. et al. Diabetes 52, 573–577 (2003).
Silander, K. et al. Diabetes 53, 1141–1149 (2004).
Love-Gregory, L.D. et al. Diabetes 53, 1134–1140 (2004).
Grant, S.F. et al. Nat. Genet. 38, 320–323 (2006).
Minton, J.A. et al. Diabetes 51, 1287–1290 (2002).
Inoue, H. et al. Nat. Genet. 20, 143–148 (1998).
Strom, T.M. et al. Hum. Mol. Genet. 7, 2021–2028 (1998).
Riggs, A.C. et al. Diabetologia 48, 2313–2321 (2005).
Ishihara, H. et al. Hum. Mol. Genet. 13, 1159–1170 (2004).
Karasik, A. et al. Diabetes Care 12, 135–138 (1989).
Yamada, T. et al. Hum. Mol. Genet. 15, 1600–1609 (2006).
Ozcan, U. et al. Science. 313, 1137–1140 (2006).
Altshuler, D. et al. Nat. Genet. 26, 76–80 (2000).
We thank all study participants. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the UK Medical Research Council (MRC) grant G0000934 and the Wellcome Trust grant 068545/Z/02. The Ashkenazi population was collected by the Israeli Diabetes Research Group, funded by the Russell Berrie Foundation, D-Cure, Diabetes Care in Israel, Israel Ministry of Health and an unrestricted research grant from Novo-Nordisk. The Wellcome Trust and Diabetes UK funded the Warren 2 study. The work on the Cambridgeshire case-control, Ely, ADDITION and EPIC-Norfolk studies was funded by support from the Wellcome Trust and MRC. We are grateful to S. Griffin, MRC Epidemiology Unit for assistance with the ADDITION study and to S. O'Rahilly and M. Sampson for their contribution to the Warren 2 study. The UK type 2 diabetes case/control collection (Go-DARTS2) was funded by the Wellcome Trust. C.N.A.P. and A.D.M. are supported by the Scottish Executive Chief Scientist's Office as part of the Generation Scotland initiative. Illumina genotyping was done by P. Deloukas's laboratory at the Wellcome Trust Sanger Institute. I. Blech. and K.A.F. are funded by the Wellcome Trust. I.B. acknowledges support from EU FP6 funding (contract number LSHM-CT-2003-503041). A.T.H. is a Wellcome Trust Research Leave Fellow. M.N.W. is a Vandervell Foundation Research Fellow. S.L.D. is funded by the British Heart Foundation. None of the sponsors or funders had any role in the design and conduct of the study, in the collection, analysis and interpretation of the data or in the preparation, review or approval of the manuscript.
The authors declare no competing financial interests.
About this article
Cite this article
Sandhu, M., Weedon, M., Fawcett, K. et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 39, 951–953 (2007) doi:10.1038/ng2067
Contemplating the role of genetic variants of HHEX, CDKAL1, WFS1 and SLC30A8 genes of TYPE-2 diabetes in Asians ethnic groups
Gene Reports (2019)
The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects
Endocrine, Metabolic & Immune Disorders - Drug Targets (2019)
Genetic Variants Associated with the Development of Type 2 Diabetes: Approaches to Their Identification
Annals of the Russian academy of medical sciences (2019)
Canadian Journal of Diabetes (2019)
Recent advances and perspectives in next generation sequencing application to the genetic research of type 2 diabetes
World Journal of Diabetes (2019)